Kelley Boucher - 09 Jun 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief People Officer
Signature: /s/ David Watson, attorney-in-fact for Kelley Boucher
Issuer symbol: APLS
Transactions as of: 09 Jun 2025
Net transactions value: +$1,306,808
Form type: 4
Filing time: 11 Jun 2025, 16:27:14 UTC
Previous filing: 29 May 2025
Next filing: 03 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Boucher Kelley	Chief People Officer	C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM	/s/ David Watson, attorney-in-fact for Kelley Boucher	11 Jun 2025	0002070437

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+45,095	+204%	$0.000000	67,182	09 Jun 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$1,306,808	+67,396		$19.39	67,396	09 Jun 2025	Common Stock	67,396	$19.39	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents an award of Restricted Stock Units granted June 9, 2025, that vests annually from grant date over a four-year period subject to continued service.
F2	This represents a stock option award granted June 9, 2025 that vests over a four-year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.